Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one…
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall…
A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it. These five names span telecom, real estate, consumer staples, utilities, and…
Three of these six income stocks beat current Treasury bill yields, but a higher number on the label does not settle the argument once taxes, reinvestment risk, and dividend safety enter the…
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp…
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar…
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…
Treasuries now offer a yield that dividend investors once bragged about, which raises a question most retirees avoid asking: does an equity income portfolio actually come out ahead after risk, taxes, and…
The 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,359.12 over the next 12 months. With the stock at $1,142.85, that implies 18.92% upside. Lilly wins…
When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory,…
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Three blue-chip dividend stocks sitting in a taxable account hand a portion of every payout straight to the IRS, but the account type holding them changes that math completely. Here is what…
From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash…
Replacing a $160,000 salary with dividends at 58 sounds like a single math problem, but the required portfolio swings by millions depending on which yield tier you choose, and the tier that…
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only…
